Published in Cancer Res on November 01, 1988
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest (1994) 1.97
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer (2005) 1.49
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci U S A (1992) 1.29
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol (2009) 1.13
Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A (1998) 1.11
Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system. Nucleic Acids Res (1990) 1.08
Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. Nucleic Acids Res (1995) 1.03
Study of the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy. Nucleic Acids Res (1998) 0.98
Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase. Nucleic Acids Res (2008) 0.97
Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect (1993) 0.96
Peptide targeting of platinum anti-cancer drugs. Bioconjug Chem (2009) 0.94
Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer (2009) 0.90
Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res (1995) 0.88
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol (2015) 0.88
Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutants. DNA Repair (Amst) (2010) 0.86
Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts. Nucleic Acids Res (1992) 0.84
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82
Copper-free click-chemistry platform to functionalize cisplatin prodrugs. Chemistry (2014) 0.81
Differential effects of cisplatin and MNNG on dna mutants of Escherichia coli. Mutat Res (2005) 0.79
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest (1993) 0.77
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics (2016) 0.76
Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. Br J Cancer (1991) 0.75
The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes (Basel) (2017) 0.75
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry (1985) 3.67
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A (1989) 2.54
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). Proc Natl Acad Sci U S A (1981) 1.66
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer (1994) 1.49
Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res (1988) 1.32
Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry (1992) 1.24
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
DNA damage metabolism and aging. Mutat Res (1991) 1.21
Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res (1982) 1.20
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res (1990) 1.17
Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes. Inorg Chem (2000) 1.16
Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry (1995) 1.15
The isolation and properties of Pseudomonas strains growing on atropine and producing atropinesterase. Proc K Ned Akad Wet C (1971) 1.11
Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry (1995) 1.10
New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy. J Biol Inorg Chem (2000) 1.10
New antitumor-active azole-bridged dinuclear platinum(II) complexes: synthesis, characterization, crystal structures, and cytotoxic studies. Inorg Chem (2000) 1.09
Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry (1995) 1.07
Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs (1993) 1.07
Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res (1985) 1.05
The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Carcinogenesis (1985) 1.05
cis-diamminedichloroplatinum(II) induced distortion of a single and double stranded deoxydecanucleosidenonaphosphate studied by nuclear magnetic resonance. J Biomol Struct Dyn (1985) 1.02
Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost (1998) 1.01
Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol (1997) 1.00
Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis (1995) 1.00
Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci (1985) 0.99
Dinuclear alkyldiamine platinum antitumor compounds: a structure-activity relationship study. J Med Chem (2001) 0.98
Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem (1988) 0.98
Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin. Biochemistry (1999) 0.97
Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels. Carcinogenesis (1989) 0.95
Conformational analysis of the adduct cis-[Pt(NH3)2 d(GpG)]+ in aqueous solution. A high field (500-300 MHz) nuclear magnetic resonance investigation. Nucleic Acids Res (1982) 0.93
Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Radiat Oncol Biol Phys (1990) 0.93
Cisplatin complexes with phosphatidylserine in membranes. Biochemistry (1997) 0.92
Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. Cancer Res (1987) 0.92
Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer (1997) 0.92
Platinum(II)-based coordination compounds as nucleic acid labeling reagents: synthesis, reactivity, and applications in hybridization assays. Chembiochem (2003) 0.91
Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays. Thromb Haemost (1994) 0.91
Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding. Chem Biol Interact (1985) 0.90
Binding of nitrite and its reductive activation to nitric oxide at biomimetic copper centers. J Biol Inorg Chem (2000) 0.90
Repair of damage by ultraviolet radiation in xeroderma pigmentosum cell strains of complementation groups E and F. Mutat Res (1980) 0.89
Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med (2001) 0.89
Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst (1996) 0.88
The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim Biophys Acta (1996) 0.85
DNA adducts, mutant frequencies, and mutation spectra in various organs of lambda lacZ mice exposed to ethylating agents. Environ Mol Mutagen (1998) 0.85
Influence of temperature on platinum binding to DNA, cell killing, and mutation induction in Escherichia coli K-12 cells treated with cis-diamminedichloroplatinum(II). Cancer Res (1982) 0.85
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res (1998) 0.85
Reaction of DNA oligonucleotides with [Pt(dien)GSMe]2+ (GSMe = S-methylated glutathione) and cis-[Pt(NH3)2(GSMe)2]2+: evidence of oligonucleotide platination via sulfur-coordinated platinum intermediates. J Biol Inorg Chem (2000) 0.84
Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. IARC Sci Publ (1986) 0.83
Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer (1999) 0.83
Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin. Int J Clin Pharmacol Ther (2009) 0.82
Neurological manifestations of hypothyroidism. Pa Med (1970) 0.82
cis-Platinum induced distortions in DNA. Conformational analysis of d(GpCpG) and cis-pt(NH3)2[d(GpCpG)], studied by 500-MHz NMR. Eur J Biochem (1983) 0.82
Problems in the therapy of Soman poisoning. Fundam Appl Toxicol (1983) 0.82
Different rates of restoration of the repair capacity in complementing xeroderma pigmentosum cells after fusion. Exp Cell Res (1981) 0.82
A comparative study of the atropinesterases of nine Pseudomonas strains. Proc K Ned Akad Wet C (1971) 0.82
Molecular dosimetry of genotoxic damage. Arch Toxicol Suppl (1989) 0.82
A 1H and 31P NMR study of cis-Pt(NH3)2[d(CpGpG)-N7(2),N7(3)]. The influence of a 5'-terminal cytosine, on the structure of the cis-Pt(NH3)2[d(GpG)-N7,N7] intrastrand cross-link. Eur J Biochem (1985) 0.82
Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination. J Thromb Thrombolysis (2000) 0.82
DNA adducts of cisplatin and carboplatin in tissues of cancer patients. IARC Sci Publ (1988) 0.81
A novel DNA structure induced by the anticancer bisplatinum compound crosslinked to a GpC site in DNA. Nat Struct Biol (1995) 0.81
The new anticancer drug [(2R)-aminomethylpyrrolidine](1, 1-cyclobutanedicarboxylato)platinum(II) and its toxic S enantiomer do interact differently with nucleic acids. J Biol Inorg Chem (1999) 0.80
Methods for detection of DNA lesions induced by genotoxic agents; developments, and applications in monitoring human exposure. Prog Clin Biol Res (1991) 0.80
Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients. Anticancer Drugs (1998) 0.80
Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis (1992) 0.80
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280. Drug Dev Ind Pharm (2003) 0.80
Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Carcinogenesis (1997) 0.80
Studies on a DNA photoreactivating enzyme from Streptomyces griseus. II. Purification of the enzyme. Biochim Biophys Acta (1975) 0.79
Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anticancer Drugs (1994) 0.79
Structural effect of intra-strand cisplatin-crosslink on palindromic DNA sequences. J Biomol Struct Dyn (1996) 0.79
Tuning the rotational behavior of lopsided heterocyclic nitrogen ligands (L) in octahedral cis-[Ru(bpy)2(L)2](PF6)2 complexes. A variable-temperature 1H NMR study. Inorg Chem (2000) 0.79
Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res (1993) 0.79
DNA methods for detecting and analyzing mutations in vivo. Mutat Res (1987) 0.78
Laparoscopic elective treatment of diverticular disease. A comparison between laparoscopic-assisted and resection-facilitated techniques. Surg Endosc (2000) 0.78
UV-induced DNA excision repair in rat fibroblasts during immortalization and terminal differentiation in vitro. Exp Cell Res (1986) 0.78
Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis (1991) 0.78
Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol (1992) 0.78
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutat Res (1987) 0.78
The new antitumor compound, cis-[Pt(NH3)2(4-methylpyridine)Cl]Cl, does not form N7,N7-d(GpG) chelates with DNA. An unexpected preference for platinum binding at the 5'G in d(GpG). J Inorg Biochem (1990) 0.78
Reaction products from platinum(IV) amine compounds and 5'-GMP are mainly bis(5'-GMP)platinum(II) amine adducts. J Inorg Biochem (1986) 0.78
Persistence of the anti-cholinesterase soman in rats; antagonism with a non-toxic simulator of this organophosphate. Eur J Pharmacol (1981) 0.78
Induction and disappearance of DNA strand breaks and/or alkali-labile sites in human lymphocytes exposed to N-ethyl-N-nitrosourea. Carcinogenesis (1991) 0.78
The age of stored red blood cell concentrates at the time of transfusion. Transfus Med (2005) 0.78
Hydrodynamic characterization of the size and shape of atropinesterase from Pseudomonas putida. Biochim Biophys Acta (1987) 0.78
[Pt(dien)]2+ migrates intramolecularly from methionine S to imidazole Nepsilon2 in the peptides H-His-Gly-Met-OH and Ac-His-Ala-Ala-Ala-Met-NHPh. J Biol Inorg Chem (1999) 0.78
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res (1992) 0.77
Age-dependent accumulation of alkali-labile sites in DNA of post-mitotic but not in that of mitotic rat liver cells. Mech Ageing Dev (1988) 0.77
A simple method for the inactivation of monofunctionally DNA-bound cis-diamminedichloroplatinum (II). J Inorg Biochem (1984) 0.77
Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. J Inorg Biochem (1995) 0.77